Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jan 31:18:eRW4686.
doi: 10.31744/einstein_journal/2020RW4686. eCollection 2020.

Pharmaceutical care-based interventions in type 2 diabetes mellitus : a systematic review and meta-analysis of randomized clinical trials

[Article in English, Portuguese]
Marcel Nogueira  1 , Leonardo Jun Otuyama  1 , Priscilla Alves Rocha  1 , Vanusa Barbosa Pinto  1
Affiliations
Meta-Analysis

Pharmaceutical care-based interventions in type 2 diabetes mellitus : a systematic review and meta-analysis of randomized clinical trials

[Article in English, Portuguese]
Marcel Nogueira et al. Einstein (Sao Paulo). .

Abstract
in English, Portuguese

Objective: To investigate the impact of pharmaceutical care-based interventions on type 2 diabetes mellitus .

Methods: PubMed®, Cochrane and Web of Science data bases were searched for randomized controlled clinical trials. Studies evaluating pharmaceutical care-based interventions in type 2 diabetes mellitus published between 2012 and 2017 were included. Glycated hemoglobin was defined as the primary endpoint; blood pressure, triglycerides and cholesterol as secondary endpoints. The random effects model was used in meta-analysis.

Results: Fifteen trials involving 2,325 participants were included. Meta-analysis revealed considerable heterogeneity (I2>97%; p<0.001), reduction in glycated hemoglobin (-1.07%; 95%CI: -1.32; -0.83; p<0.001), glucose (-29.91mg/dL; 95%CI: -43.2; -16.6; p<0.001), triglyceride (19.8mg/dL; 95%CI: -36.6; -3.04; p=0.021), systolic blood pressure (-4.65mmHg; 95%CI: -8.9; -0.4; p=0.032) levels, and increased HDL levels (4.43mg/dL; 95%CI: 0.16; 8.70; p=0.042).

Conclusion: Pharmaceutical care-based clincal and education interventions have significant impact on type 2 diabetes mellitus . The tools Summary of Diabetes Self-Care Activities and the Morisky Medication Adherence Scale may be useful to monitor patients.

Objetivo: Identificar o impacto das intervenções providenciadas pelo cuidado farmacêutico no diabetes mellitus tipo 2.

Métodos: Buscas por ensaios clínicos randomizados controlados foram realizadas nas bases PubMed®, Cochrane e Web of Science . Foram incluídos estudos publicados entre 2012 e 2017, que avaliaram o impacto do cuidado farmacêutico no diabetes mellitus tipo 2. A hemoglobina glicada foi o desfecho primário, e os secundários foram pressão arterial, triglicérides e colesterol. O modelo de efeitos aleatórios foi utilizado na metanálise.

Resultados: Foram incluídos 15 estudos envolvendo 2.325 participantes. A metanálise demonstrou heterogeneidade elevada (I2>97%; p<0,001), redução nos níveis de hemoglobina glicada (-1,07%; IC95%: -1,32; -0,83; p<0,001), glicose (-29,91mg/dL; IC95%: -43,2; -16,6; p<0,001), triglicérides (19,8mg/dL; IC95%: -36,6; -3,04; p=0,021), pressão arterial sistólica (-4,65mmHg; IC95%: -8,9; -0,4; p=0,032) e aumento do colesterol HDL (4,43mg/dL; IC95%: 0,16; 8,70; p=0,042).

Conclusão: As intervenções clínicas e educacionais providenciadas pelo cuidado farmacêutico têm impacto significativo no diabetes mellitus tipo 2. Ferramentas como o Summary of Diabetes Self-Care Activities e a Morisky Medication Adherence Scale podem ser úteis no acompanhamento dos pacientes.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Study selection flowchart
HbA1c: Glycated hemoglobin.
Figure 2
Figure 2. Risk of bias
Figure 3
Figure 3. Forest plot
Figura 1
Figura 1. Fluxograma de seleção dos estudos
HbA1c: hemoglobina glicada.
Figura 2
Figura 2. Risco de viés
Figura 3
Figura 3. Forest plot
See this image and copyright information in PMC

References

    1. 1. American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(Suppl1):S4-5.
    2. American Diabetes Association Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(Suppl1):S4–S5. - PubMed
    1. 2. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228-36. Review. - PubMed
    2. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–236. Review. - PubMed
    1. 3. Smith KB, Smith MS. Obesity statistics. Prim Care. 2016;43(1):121-35. Review. - PubMed
    2. Smith KB, Smith MS. Obesity statistics. Prim Care. 2016;43(1):121–135. Review. - PubMed
    1. 4. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.
    2. International Diabetes Federation . IDF diabetes atlas. 7th. Brussels, Belgium: International Diabetes Federation; 2015.
    1. 5. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009; 35(6):1014-22. - PubMed
    2. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ. 2009;35(6):1014–1022. - PubMed

MeSH terms